Mai-Britt Zocca - 09 Aug 2023 Form 4 Insider Report for IO Biotech, Inc. (IOBT)

Role: Chief Executive Officer, Director
Signature: /s/ Brian Burkavage, Attorney-in-Fact for Mai-Britt Zocca
Issuer symbol: IOBT
Transactions as of: 09 Aug 2023
Net transactions value: +$75,000
Form type: 4
Filing time: 09 Aug 2023, 20:43:49 UTC
Previous filing: 22 Mar 2023
Next filing: 18 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IOBT	Common Stock	Award	$70,370	+37,037	+10462%	$1.90	37,391	09 Aug 2023	Direct
holding	IOBT	Common Stock						26,580	09 Aug 2023	Zocca Consulting ApS	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IOBT	Warrants (Right to Buy)	Award	$4,630	+37,037		$0.1250^*	37,037	09 Aug 2023	Common Stock	37,037	$2.47	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is the sole owner of Zocca Consulting ApS and, in such capacity, may be deemed to beneficially own the shares held directly by Zocca Consulting ApS. The reporting person disclaims beneficial ownership of the shares held directly by Zocca Consulting ApS except to the extent of her pecuniary interest therein.
F2	These Warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023.